UGT2B29P: A Drug Target / Disease Biomarker (G54568)

Target Name: UGT2B29P

NCBI ID: G54568

UGT2B29P

Other Name(s): UDP glucuronosyltransferase family 2 member B29, pseudogene | UDP glucuronosyltransferase 2 family, polypeptide B29 pseudogene

UGT2B29P: A Drug Target / Disease Biomarker

UGT2B29P is a gene that encodes a protein known as UGT2B29P. UGT2B29P is a member of the UGT family, which is responsible for metabolizing a wide variety of drugs and other substances in the body. The function of UGT2B29P is to encode the 29th protein of the UGT family.

UGT2B29P is a drug target (or biomarker) because it is involved in the metabolism of a wide variety of drugs, including many anti-cancer drugs. The primary function of UGT2B29P is to metabolize these drugs, which allows them to be removed from the body. However, some drugs can be metabolized by UGT2B29P to produce metabolites that are potentially harmful. Therefore, UGT2B29P is an important protein that can be targeted by drugs that are used to treat cancer.

Research has shown that UGT2B29P is involved in many different drug metabolism pathways. For example, UGT2B29P is involved in the metabolism of the chemotherapy drug cisapride, which is used to treat certain types of cancer. UGT2B29P is also involved in the metabolism of the anti-inflammatory drug celecoxib, which is used to treat rheumatoid arthritis and other conditions.

In addition to its role in drug metabolism, UGT2B29P is also involved in the regulation of cellular processes that are important for the growth, development, and survival of cells. For example, UGT2B29P is involved in the development and maintenance of the blood-brain barrier, which is a barrier that separates the brain from the rest of the body and helps to protect it from harmful substances.

Based on these findings, UGT2B29P is an attractive drug target (or biomarker) for cancer researchers. Researchers are working to develop drugs that can specifically target UGT2B29P and inhibit its function in drug metabolism. These drugs can then be used to treat a wide variety of cancer types, including breast, lung, and ovarian cancers.

Overall, UGT2B29P is a drug target (or biomarker) that is important for the development of new cancer treatments. Further research is needed to fully understand the role of UGT2B29P in drug metabolism and to develop effective treatments for cancer.

Protein Name: UDP Glucuronosyltransferase Family 2 Member B29, Pseudogene

The "UGT2B29P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGT2B29P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets